These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19350463)

  • 21. Phase I clinical trials of anticancer drugs in healthy volunteers: need for critical consideration.
    Gupta P; Gupta V; Gupta YK
    Indian J Pharmacol; 2012; 44(4):540-2. PubMed ID: 23087528
    [No Abstract]   [Full Text] [Related]  

  • 22. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive designs in clinical drug development--SMi's third annual conference. 4-5 February 2009, London, UK.
    Padhiar M
    IDrugs; 2009 Apr; 12(4):230-2. PubMed ID: 19350466
    [No Abstract]   [Full Text] [Related]  

  • 24. Inquiries in Britain uncover loopholes in drug trials.
    Rosenthal E
    N Y Times Web; 2006 Aug; ():A3. PubMed ID: 16909495
    [No Abstract]   [Full Text] [Related]  

  • 25. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
    Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP
    Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2nd State of the Art Conference on Methods in Phase I. Bron, France, February 9-10, 1995. Abstracts.
    Clin Trials Metaanal; 1994 Dec; 29(4):247-310. PubMed ID: 10184341
    [No Abstract]   [Full Text] [Related]  

  • 27. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted agents: how to select the winners in preclinical and early clinical studies?
    Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
    Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium.
    Benjamin RK; Hochberg FH; Fox E; Bungay PM; Elmquist WF; Stewart CF; Gallo JM; Collins JM; Pelletier RP; de Groot JF; Hickner RC; Cavus I; Grossman SA; Colvin OM
    Neuro Oncol; 2004 Jan; 6(1):65-74. PubMed ID: 14769143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The thorough QT study: Is its demise on the horizon?
    Sager PT; Kowey P
    Ann Noninvasive Electrocardiol; 2014 Jan; 19(1):1-3. PubMed ID: 24397828
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
    Maneely D
    IDrugs; 2003 Jul; 6(7):650-1. PubMed ID: 12906014
    [No Abstract]   [Full Text] [Related]  

  • 33. Pain therapeutics--SMi's Ninth Annual Conference 8-9 June 2009, London, UK.
    Kirkham K
    IDrugs; 2009 Aug; 12(8):489-91. PubMed ID: 19629882
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.
    Muller PY
    Adv Drug Deliv Rev; 2011 Jun; 63(7):511-7. PubMed ID: 21034787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?
    Horvath CJ; Milton MN
    Toxicol Pathol; 2009 Apr; 37(3):372-83. PubMed ID: 19244218
    [No Abstract]   [Full Text] [Related]  

  • 36. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New requirements for phase I trials: a challenge for Italian clinical research.
    Marchesi E; Monti M; Nanni O; Bassi L; Piccinni-Leopardi M; Cagnazzo C
    Tumori; 2018; 104(1):15-21. PubMed ID: 28799641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.